| Literature DB >> 24366501 |
Pieter W Smit, Ivo Elliott, Rosanna W Peeling, David Mabey, Paul N Newton.
Abstract
Tropical infectious diseases diagnosis and surveillance are often hampered by difficulties of sample collection and transportation. Filter paper potentially provides a useful medium to help overcome such problems. We reviewed the literature on the use of filter paper, focusing on the evaluation of nucleic acid and serological assays for diagnosis of infectious diseases using dried blood spots (DBS) compared with recognized gold standards. We reviewed 296 eligible studies and included 101 studies evaluating DBS and 192 studies on other aspects of filter paper use. We also discuss the use of filter paper with other body fluids and for tropical veterinary medicine. In general, DBS perform with sensitivities and specificities similar or only slightly inferior to gold standard sample types. However, important problems were revealed with the uncritical use of DBS, inappropriate statistical analysis, and lack of standardized methodology. DBS have great potential to empower healthcare workers by making laboratory-based diagnostic tests more readily accessible, but additional and more rigorous research is needed.Entities:
Mesh:
Year: 2013 PMID: 24366501 PMCID: PMC3919219 DOI: 10.4269/ajtmh.13-0463
Source DB: PubMed Journal: Am J Trop Med Hyg ISSN: 0002-9637 Impact factor: 2.345
| We searched the electronic databases MEDLINE and Embase for studies published between 1980 and December 13, 2011. Publications that evaluated the use of DBS as alternatives for gold standard samples for human infectious disease diagnosis were included. We excluded in-house assays for HIV, Hepatitis B and C, cytomegalovirus, measles, and rubella because of the existence of well-recognized commercially available assays for these pathogens. Details of excluded in-house assays are provided in |
Figure 1.Selection of reports included in the analysis.
Summary of studies evaluating serological and NAAT diagnosis of HIV comparing DBS with whole blood (DNA) and serum/plasma (RNA)
| Assay type | HIV-1 detection | No. of studies | Sensitivity (%) | Specificity (%) | Refs. |
|---|---|---|---|---|---|
| Serology | Ab/Ag | 7 | 100 | 98.7–100 | |
| Serology | Ag (p24) | 5 | 84–98.8 | 98–100 | |
| Serology | Western blot | 1 | 92 | 100 | |
| NAAT | DNA | 6 | 97–100 | 99.6–100 | |
| NAAT | RNA | 6 | 99.2–100 | 95.6–100 | |
| NAAT | DNA and RNA | 3 | 99.7–100 | 100 |
Summary of studies evaluating DBS for Flavivirus and chikungunya diagnosis
| Disease, assay type and country | Ref. | Number of samples/filter paper type | Test | Sensitivity (%) | Specificity (%) | Notes |
|---|---|---|---|---|---|---|
| Puerto Rico | NR/unspecified filter paper | In-house IgM and IgG ELISA | 97 IgM; 96 IgG | 97 IgM; 91 IgG | IgM results are for weak positives (OD = 0.2–0.35). | |
| Vietnam | 781 patients/Whatman 903 | Dengue fever IgM and IgG ELISA (Focus Diagnostics) | NR | NR | DBS correlated poorly with serum, particularly for acute 1° and acute 2° dengue infection. However, correlation was inappropriate for analysis. | |
| Cuba | 189 patients/ Whatman 2992 | In-house ultramicro-ELISA | 92.1 | 98.6 | ||
| French Guiana | 130 patients/ Whatman paper | In-house ELISA IgM | 89 | 94 | IgM stable at room temperature for 1 month and at 4°C for > 2 months. | |
| Nicaragua | 169 patients/ Whatman No.3 | In-house ELISA IgM, IgA, and IgG | 96 IgM; 93 IgA; 86 IgG | 89 IgM; 89 IgA; 92 IgG | Detecting IgM or IgA is useful for acute dengue diagnosis. IgG is optimal for dengue incidence surveillance. Danger of cross-reactivity of IgG with other flaviviruses. | |
| Cuba | 52 samples/ Nobuto paper | In-house PCR | 93 | 100 | Samples prepared with blood spiked with dengue virus. Lower limit of detection for dengue serotype 2 than 3. RNA stable at 37°C for 1 year. Risk of viral infectivity from paper for 48 hours at room temperature. | |
| French Guiana | 130 patients/ Whatman paper | In-house PCR | 90.7 | 82.9 | Serotyping also performed. Sensitivity and specificity were highest during the first 4 days of infection, falling rapidly thereafter. However, virus still detectable in 27% up to day 12 in capillary but not venous samples. | |
| Thailand | 243 patients/ Nobuto paper | In-house ELISA and in-house HI | 72 and 26/38 and 33 during epidemic and non-epidemic periods | NR | ELISA and HI tests were compared with serum. ELISA was more sensitive during epidemic periods. Newer commercially available assays are available but have so far not been evaluated on DBS. | |
| La Reunion | 144 patients/ Whatman 903 | IgG ELISA (National Arbovirus Reference Laboratory, Lyon, France) | 97.9 | 100 | Seroprevalence study. IgM also detected with similar OD thresholds as sera, but no independent quality control performed. | |
HI = hemagglutination inhibition; NR = not recorded; OD = optical density.
Summary of studies evaluating DBS for malaria (malaria NAAT assays)
| Country | Ref. | Sample size/filter paper | Assay | Pf | Po | Pv | Pm | Unknown | Sensitivity (%) | Specificity (%) | Reference test | Notes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Thailand | 56 samples/ Whatman 903 | In-house | ✓ | 94.6 | NR | Thin/thick blood smear | ||||||
| Malaysia | 166 patients/ Whatman 3MM | In-house (adjusted) | ✓ | ✓ | 97.4 | NR | Thick blood smear | |||||
| Malaysia | 129 patients/ Whatman 3MM | In-house | ✓ | ✓ | ✓ | ✓ | NR | NR | Limit of detection: 6 parasites/μL. | |||
| Singapore | 52 patients/ Whatman No.1 | In-house | ✓ | ✓ | 100 | 100 | Thin/thick blood smear | Limit of detection: 4 parasites/μL. | ||||
| Malaysia, Myanmar, Thailand | 81 patients/ Isocode cards | In-house | ✓ | ✓ | ✓ | 94.1 (Pf); 100 (Pv) | 100 (Pf); 99.1 (Pv) | Thin/thick blood smear | 1 of 1 Po samples detected. | |||
| Thailand | 136 patients/ Whatman 3MM | Multiplex PCR | ✓ | ✓ | 100 (Pf); 92.7 (Pv) | 100 (Pf); 100 (Pv) | Consensus of three PCR assays | Specificity of all three assays lower (93.8–97%) compared with microscopy. Microscopy had 90.7–92.5% sensitivity and 91.5–100% specificity. | ||||
| Nested PCR | ✓ | ✓ | 100 (Pf); 100 (Pv) | 99 (Pf); 100 (Pv) | ||||||||
| RT-PCR | ✓ | ✓ | 100 (Pf); 100 (Pv) | 100 (Pf); 100 (Pv) | ||||||||
| Saudi Arabia | 118 patients/ Whatman paper | In-house | ✓ | 73 | NR | Thin/thick blood smear | Several microscopy-negative samples were positive on DBS PCR. | |||||
| Thailand, Zimbabwe | 156 patients/ FTA card | In-house | ✓ | 97.8 | 100 | Thin/thick blood smear | Limit of detection: 10 copies/reaction. | |||||
| Iran | 75 patients/ DNA Banking Card | In-house | ✓ | ✓ | 97 | 100 | Thin/thick blood smear | Whole blood was more sensitive but less specific than DBS compared with microscopy (100% sensitivity, 95.2% specificity). | ||||
| Kenya | 356 patients/ Whatman 3MM | In-house | ✓ | 100 | 79 | Thin/thick blood smear | Low specificity potentially caused by insufficient microscopy expertise. |
Pf = Plasmodium falciparum; Pm = P. malariae; Po = P. ovale; Pv = P. vivax; RT-PCR = real time PCR; NR = not reported.
Summary of studies evaluating DBS for parasites other than malaria
| Disease, assay type, and country | Ref. | Number of samples/filter paper type | Test | Sensitivity (%) | Specificity (%) | Notes |
|---|---|---|---|---|---|---|
| 94 patients/ Whatman 903 | In-house EIA | 92 | 77 | |||
| India | ||||||
| Ghana | 1,808 patients/Og4C3 paper | Og4C3 ELISA ( | 50.3 | 96.4 | ||
| Sri Lanka | 60 patients/ Nobotu 1 | Og4C3 ELISA ( | 97 | NR | ||
| India | 30 patients/ Whatman No.3 | Og4C3 ELISA ( | 76.6–93.3 | 100 | Time of the day at which samples are collected impacts sensitivity. | |
| India, Egypt, Haiti, Kenya, Papua New Guinea, Sri Lanka | 188 patients/Whatman No.3 | Og4C3 ELISA ( | NR | NR | ||
| Egypt | 81 samples/filter paper (Tropical Biotechnology) | Filariasis ( | 91 ( | NR | Based on a panel of known positives. | |
| Uganda | 66 patients/Whatman 3MM | Brugia Rapid (Reszon Diagnostics) | 79 | NR | Significant cross-reactivity with other filarial infections. | |
| Indonesia | 36 patients/ Whatman 3MM | In-house PCR and ELISA combination | 86 | NR | PCR-ELISA produced comparable results compared with DNA Detection Test Strips (Roche, Germany). | |
| Malaysia | 21 patients/ Whatman 3MM | In-house PCR | NR | NR | ||
| Brazil | 12 patients/ Whatman paper | In-house PCR | NR | NR | PCR was able to distinguish between | |
| Cameroon | 68 patients/ NR | In-house PCR | 96 | NR | High specificity. No cross-reactivity with other filarial species. Limit of detection 1 microfilaria/20 μL whole blood (as DBS). | |
| Sudan | 100 patients/ NR | Micro-CATT (ITM Antwerp) | 91 | NR | ||
| Central African Republic, Ivory Coast | 940 patients/ Whatman No.4 | Micro-CATT (ITM Antwerp) | 89.4–95.5 | 95.5–96.6 | Truc and others | |
| Brazil | 6,222 patients/ Whatman No.1 | In-house ELISA, IF, and HA | ELISA, 78.1; IF, 69.2; HA, 64.6 | ELISA, 99.7; IF, 99.4; HA, 99.6 | ||
| Brazil | 24 patients/ NR | Chagas Stat-Pak (ICT; Chembio Diagnostic Systems) | 100 | 100 | Chagas Stat-Pak performed on small sample size. More sensitive and specific than large-scale evaluation with serum. | |
| Argentina | 479 patients/ Whatman No.1 | In-house ELISA | NR | NR | Coltorti and others | |
| Uruguay | 1,149 patients/ Whatman No.1 | In-house ELISA | NR | NR | ||
| China | 2,482 patients/ Whatman No.1 | In-house ELISA | 96 | 87 | ||
| Portugal | 24 patients/ Whatman No.2 | In-house PCR | 71–75 | NR | 15/20 positive for patients not on treatment and 17/24 if patients on treatment included. Useful as an initial screening tool. | |
| Bolivia | 68 patients/ Whatman No.1 | In-house ELISA | NR | NR | Samples missed on DBS had the lowest ELISA readings. Samples stored for 10 years at 4°C were successfully detected. | |
| Saudi Arabia | 147 patients/ Whatman No.4 | In-house ELISA | 72–96 | 39–98 | al-Tukhi and others | |
| Brazil | 133 patients/ Whatman No.1 | In-house IF; in-house ELISA | 82; 72 | 70; 39 | ||
| Brazil | 151 patients/ Whatman No.4 | Qualicode Cysticercosis ELISA kit (Immunetics Inc.) | 80 | NR | Good agreement between serum and DBS. May be a useful initial screening test. Fall in sensitivity if filter paper was not frozen after 1 week storage. Ranges were caused by samples being processed at two sites using two methods. | |
| Mexico | 305 patients/ Whatman No. 311 | In-house ELISA | 39–66 | 87–96 | ||
| United Kingdom | 273 patients/ Whatman 903 | Eiken Toxoreagent Latex Agglutination | 98.8 | 100 | ||
Bssp = Brugia malayi and B. timori; CATT = Card Agglutination Test for Trypanosomiasis; HAT = Human African Trypanosomiasis; IF = Immunofluorescence; Wb = Wucheraria bancrofti.
Summary of studies evaluating DBS for bacteria
| Disease, assay type, and country | Ref. | Number of samples/filter paper type | Test | Sensitivity (%) | Specificity (%) | Notes |
|---|---|---|---|---|---|---|
| French Polynesia | 168 patients/ Whatman No.1 | In-house ELISA | Multibacillary 96; Paucibacillary 29 | Multibacillary 96; Paucibacillary 96 | ||
| India | 94 patients/ Whatman No.3 | In-house ELISA | Multibacillary 97; Paucibacillary 73 | Multibacillary 100; Paucibacillary 100 | Based on a cutoff of 1:40 (OD) | |
| India | 81 patients/ Whatman No.3 | MLPA (Fujirebio); in-house ELISA | 67.7 (MLPA); 76.9 (ELISA) | 98.7 (MLPA); 83.4 (ELISA); | ||
| Nepal | 200 patients/ NR | In-house ELISA | NR | NR | Earlobe capillary blood more sensitive than serum or finger-prick blood | |
| Laos | 53 scrub typhus patients; 53 murine typhus patients/ Whatman 903 | In-house ELISA | 95 IgM and 90 IgG; 91 IgM and 82 IgG | 88 IgM and 100 IgG; 100 IgM and 100 IgG | Lower antibody titers with DBS; storage at room temperature for 1 month did not affect antibody titers | |
| France | 94 patients/ Fischer Scientific paper | In-house ELISA | 100 | 100 | ||
| La Reunion | 52 patients/ Whatman 903 | MAT | 100 | 100 | DBS samples showed lower antibody titers compared with serum | |
| United States | 1,098 patients/ Whatman 903 | In-house ELISA | 96 | 94 | ||
| Tanzania | 1,037 patients/ Whatman 903 | Serodia TPPA (Fujirebio) | 98.3 | 100 | ||
| Papua New Guinea | 70 patients/ Whatman 903 | TPHA–Serodia TP kit (Fujirebio) | 96.5 | 100 | Results unaffected by up to 2 months storage | |
| Spain | 160 patients/ Whatman 2992 | NR | NR | Pearson correlation coefficient: | ||
MAT = microscopic agglutination test; MLPA = Mycobacterium leprae particle agglutination; TPHA = Treponema pallidum-specific hemagglutination test; TPPA = Treponema pallidum particle agglutination test.
Figure 2.Practical aspects and implications of using DBS. NA = nucleic acid.
Additional suggested Standards for Reporting of Diagnostic Accuracy (STARD) checklist points for DBS evaluation
| Concerns when using DBS | STARD checklist adjustments for DBS evaluations |
|---|---|
| Inconsistency in terminology | Make use of clear terminology (i.e., DBS, dried serum spots, dried urine spots, etc. or dried “sample type” spots). |
| Unclear or not reporting filter paper sample collection method | Sample collection: state the filter paper brand and weight used, which and how fluids were obtained and spotted onto filter paper, and the drying period before storage. |
| Unclear reporting of reference method and sample | Report the index sample and its collection, storage, and transportation details; provide detailed rationale for discordances in methods between index and reference test. |
| Unclear or not reporting storage and time between collecting and analyzing samples | Sample processing: state the time and storage conditions (humidity control and temperature) in the field, during transportation, and in the laboratory, preferably in a tabled manner. |
| Unclear or not reporting punch method and punch disinfection procedure | Report punching method with reference to source or manufacturer and punch disinfection procedure if used. |
| Unclear or not reporting how quantitative data was obtained from filter paper samples | For quantitative or numerical test results, indicate the calculation methods and rationale of the index and reference standard. |
| Unclear or not reporting the biological variability of samples and mean difference between index and reference sample | For quantitative test outcomes, report the mean and range of results for index and reference test. |
| Unclear or not reporting of diagnostic accuracy of quantitative test outcomes. | For quantitative test outcomes, estimates of diagnostic accuracy and measures of statistical uncertainty (e.g., 95% confidence intervals) by quantitative grouped ranges (e.g., 1,000–5,000 copies/mL). |